カテゴリ： GlobalData, 企業調査, 日本

Takara Bio Inc (4974)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Takara Bio Inc (4974) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3498
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：61
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Takara Bio Inc (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipments for life sciences research. The company sells gene amplification system and offers scientific instruments. It offers clinical development of gene therapies for cancer treatment. Takara develops and commercializes medical technologies such as cell and gene therapies for cancer and AIDS. The company also develops original research reagents, scientific instruments, and contracted research services that utilize new genetic and cell engineering technologies. It supports biotechnology research by offering basic research and drug discovery and development services. Takara is headquartered in Kusatsu, Japan.

Takara Bio Inc (4974) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Takara Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Takara Bio Inc, Medical Devices Deals, 2012 to YTD 2018 10
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Takara Bio Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Rubicon Genomics Raises USD2 Million in Venture Financing 13
Partnerships 14
Takara Bio Enters into Co-Development Agreement with Otsuka Pharma 14
Cellink Enters Research Agreement with Takara Bio Europe 15
Rubicon Genomics Enters into Distribution Agreement with Beckman Coulter Life Sciences for ThruPLEX Plasma-Seq Kits 16
WaferGen Biosystems Enters into Agreement with Luxembourg Institute of Health 17
Rubicon Genomics Enters into Distribution Agreeement with Eurofins MWG Operon 18
WaferGen Bio-systems Enters into Research Agreement with Genentech 19
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 20
Rubicon Enters Into Technology Integration Agreement With Diagenode For ChIP Sequencing Technology 21
Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 22
Licensing Agreements 23
Dong-A ST Enters into Licensing Agreement with Takara Bio 23
Takara Bio Enters into Licensing Agreement with Kyushu University 24
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 25
AmpliPhi Biosciences Enters into License Agreement with Takara Bio 26
Rubicon Genomics Enters into Licensing Agreement with SomaGenics 27
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 28
Takara Bio Enters into Licensing Agreement with ViaCyte 29
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 30
Takara Bio Expands Licensing Agreement With iPS Academia Japan 31
Takara Bio Enters Into Licensing Agreement With Cellular Dynamics International For RetroNectin 32
WaferGen Biosystems Enters Into Licensing Agreement With Rutgers University For RNA Quality Control Technology 33
Equity Offering 34
WaferGen Bio-systems Raises USD17.25 Million in Public Offering of Common Stock 34
WaferGen Biosystems Raises USD20 Million in Public Offering of Units 35
WaferGen Biosystems Completes Second Tranche Of Private Placement Of Units For US$15 Million 37
Takara Bio Raises USD112 Million in Public Offering Of Common Stock 38
Acquisition 39
Takara Bio Acquires WaferGen Bio-Systems 39
Takara Bio Acquires Rubicon Genomics for USD75 Million 41
Takara Bio Acquires Cellectis, Biotech Company 42
Takara Bio Inc – Key Competitors 43
Takara Bio Inc – Key Employees 44
Takara Bio Inc – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 46
Recent Developments 47
Strategy And Business Planning 47
Jan 30, 2018: Takara Bio: Regarding the establishment of research and manufacturing facilities for products such as regenerative medicine 47
Jan 30, 2018: Takara Bio to Establish a New Facility for the Research and Manufacturing of Regenerative Medical Products 48
Financial Announcements 49
Nov 28, 2017: Takara Bio: Consolidated Financial Statements for the Second Quarter Ended September 30, 2017 49
Product News 51
May 08, 2018: SMARTer ICELL8 technology aids in single-nuclei sequencing of triple-negative breast cancer to uncover chemoresistance evolution 51
01/17/2018: First Patient Enrolled into Phase I/II Clinical Trial of NY-ESO-1·siTCR Gene Therapy Against Synovial Sarcoma in Japan 52
Product Approvals 53
Mar 27, 2018: Announcement on product designation of NY-ESO-1·siTCR gene therapy product for synoviral sarcoma under “SAKIGAKE Designation System” by the Ministry of Health, Labour and Welfare 53
Jan 24, 2017: Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1-siTCR gene therapy in Japan 54
Clinical Trials 55
Sep 27, 2017: First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan 55
Jun 01, 2017: Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan 56
May 29, 2017: First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan 57
May 23, 2017: Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology 58
Jan 30, 2017: Takara Bio: Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan 59
Other Significant Developments 60
May 17, 2018: Takara Bio Announces Launch of Beta Cell Differentiation Service 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Takara Bio Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Takara Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Takara Bio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Takara Bio Inc, Medical Devices Deals, 2012 to YTD 2018 10
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Rubicon Genomics Raises USD2 Million in Venture Financing 13
Takara Bio Enters into Co-Development Agreement with Otsuka Pharma 14
Cellink Enters Research Agreement with Takara Bio Europe 15
Rubicon Genomics Enters into Distribution Agreement with Beckman Coulter Life Sciences for ThruPLEX Plasma-Seq Kits 16
WaferGen Biosystems Enters into Agreement with Luxembourg Institute of Health 17
Rubicon Genomics Enters into Distribution Agreeement with Eurofins MWG Operon 18
WaferGen Bio-systems Enters into Research Agreement with Genentech 19
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 20
Rubicon Enters Into Technology Integration Agreement With Diagenode For ChIP Sequencing Technology 21
Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 22
Dong-A ST Enters into Licensing Agreement with Takara Bio 23
Takara Bio Enters into Licensing Agreement with Kyushu University 24
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 25
AmpliPhi Biosciences Enters into License Agreement with Takara Bio 26
Rubicon Genomics Enters into Licensing Agreement with SomaGenics 27
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 28
Takara Bio Enters into Licensing Agreement with ViaCyte 29
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 30
Takara Bio Expands Licensing Agreement With iPS Academia Japan 31
Takara Bio Enters Into Licensing Agreement With Cellular Dynamics International For RetroNectin 32
WaferGen Biosystems Enters Into Licensing Agreement With Rutgers University For RNA Quality Control Technology 33
WaferGen Bio-systems Raises USD17.25 Million in Public Offering of Common Stock 34
WaferGen Biosystems Raises USD20 Million in Public Offering of Units 35
WaferGen Biosystems Completes Second Tranche Of Private Placement Of Units For US$15 Million 37
Takara Bio Raises USD112 Million in Public Offering Of Common Stock 38
Takara Bio Acquires WaferGen Bio-Systems 39
Takara Bio Acquires Rubicon Genomics for USD75 Million 41
Takara Bio Acquires Cellectis, Biotech Company 42
Takara Bio Inc, Key Competitors 43
Takara Bio Inc, Key Employees 44
Takara Bio Inc, Other Locations 45
Takara Bio Inc, Subsidiaries 45
Takara Bio Inc, Joint Venture 46

List of Figures
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Takara Bio Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Takara Bio Inc (4974)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Hibbett Sports Inc：戦略・SWOT・企業財務分析
    Hibbett Sports Inc - Strategy, SWOT and Corporate Finance Report Summary Hibbett Sports Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Subaru Corp (7270)：企業の財務・戦略的SWOT分析
    Subaru Corp (7270) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Braskem SA (BRKM5)：企業の財務・戦略的SWOT分析
    Braskem SA (BRKM5) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • ConocoPhillips (COP)-石油・ガス分野：企業M&A・提携分析
    Summary ConocoPhillips is an independent upstream oil and gas company. The company explore for, produce, transport and market crude oil, bitumen, natural gas, liquefied natural gas (LNG) and natural gas liquids across the world. It has assets across North America, Europe, Asia and Australia. Its ass …
  • Development Bank of Southern Africa：企業の戦略的SWOT分析
    Development Bank of Southern Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • The Hongkong and Shanghai Banking Corp Ltd：企業の戦略的SWOT分析
    The Hongkong and Shanghai Banking Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Menicon Co Ltd (7780)-医療機器分野：企業M&A・提携分析
    Summary Menicon Co Ltd (Menicon) is a medical device company that manufactures, export, import and markets ophthalmic products. The company’s products include soft contact lens, hard contact lens, astigmatic contact lens and bifocal contact lenses, among others. It offers contact lens care products …
  • Kirby Corporation：企業の戦略・SWOT・財務情報
    Kirby Corporation - Strategy, SWOT and Corporate Finance Report Summary Kirby Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • NGK Spark Plug Co Ltd：戦略・SWOT・企業財務分析
    NGK Spark Plug Co Ltd - Strategy, SWOT and Corporate Finance Report Summary NGK Spark Plug Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Grupo Nutresa SA (NUTRESA)：企業の財務・戦略的SWOT分析
    Grupo Nutresa SA (NUTRESA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • NGEx Resources Inc：企業のM&A・事業提携・投資動向
    NGEx Resources Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NGEx Resources Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Fossil Group, Inc. (FOSL)：企業の財務・戦略的SWOT分析
    Fossil Group, Inc. (FOSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Canon Medical Systems Corp：企業の戦略的SWOT分析
    Canon Medical Systems Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Steel Authority Of India Ltd：企業の戦略・SWOT・財務分析
    Steel Authority Of India Ltd - Strategy, SWOT and Corporate Finance Report Summary Steel Authority Of India Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Bangladesh Power Development Board-エネルギー分野：企業M&A・提携分析
    Summary Bangladesh Power Development Board (BPDB) is an integrated energy statutory board. It generates electricity through owned power plants and procures electricity from public and private generation companies. The board utilizes gas, coal, hydro, furnace oil, and diesel as fuel source for electr …
  • Aalberts Industries NV：企業のM&A・事業提携・投資動向
    Aalberts Industries NV - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Aalberts Industries NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Alkermes Plc (ALKS)：企業の財務・戦略的SWOT分析
    Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • TD Ameritrade Holding Corporation：企業の戦略・SWOT・財務情報
    TD Ameritrade Holding Corporation - Strategy, SWOT and Corporate Finance Report Summary TD Ameritrade Holding Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • AIMM Therapeutics BV-製薬・医療分野：企業M&A・提携分析
    Summary AIMM Therapeutics BV (AIMM Therapeutics) is a biotechnology company that develops progressive approach to the discovery of therapeutic antibodies for the treatment of cancer and infectious diseases. The company offers research programs for prevention and treatment of diseases with medical ne …
  • BioVendor – Laboratorni Medicina as：製薬・医療：M&Aディール及び事業提携情報
    Summary BioVendor - Laboratorni Medicina as (BioVendor) is a developer and manufacturer of immunoassays, recombinant protiens, antibodies and endotoxin-removal products. The company provides products such as immunoassays, proteins, antibodies, endotoxin removal products, endotoxin detection products …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆